Melanoma Clinical Trial
Dabrafenib and/or Trametinib Rollover Study
Summary
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
Eligibility Criteria
Inclusion Criteria:
Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective.
In the opinion of the Investigator would benefit from continued treatment.
Exclusion Criteria:
Patient has been previously permanently discontinued from study treatment in the parent protocol.
Patient's indication is commercially available and reimbursed in the local country.
Patient currently has unresolved toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 27 Locations for this study
Scottsdale Arizona, 85258, United States More Info
Principal Investigator
Bethesda Maryland, 20892, United States More Info
Principal Investigator
Columbus Ohio, 43210, United States
Dallas Texas, 75251, United States
Buenos Aires , C1125, Argentina
Innsbruck , A-602, Austria
Beijing , 10003, China
Copenhagen , DK-21, Denmark
Lyon , 69373, France
Nantes Cedex 1 , 44093, France
Paris , 75970, France
Villejuif , 94800, France
Mannheim Baden Wuerttemberg, 68305, Germany
Berlin , 13353, Germany
Hamburg , 20246, Germany
Heidelberg , 69120, Germany
Budapest , H 112, Hungary
Debrecen , 4032, Hungary
Kashiwa Chiba, 277 8, Japan
Chuo ku Tokyo, 104 0, Japan
Rotterdam , 3075 , Netherlands
Utrecht , 3584C, Netherlands
Barcelona Catalunya, 08035, Spain
Madrid , 28040, Spain
Madrid , 28041, Spain
Madrid , 28050, Spain
Songkla , 90110, Thailand
How clear is this clinincal trial information?